In the past week, CHRS stock has gone down by -0.64%, with a monthly decline of -7.10% and a quarterly plunge of -12.76%. The volatility ratio for the week is 5.06%, and the volatility levels for the last 30 days are 5.95% for Coherus Oncology Inc The simple moving average for the past 20 days is -4.36% for CHRS’s stock, with a -29.43% simple moving average for the past 200 days.
Is It Worth Investing in Coherus Oncology Inc (NASDAQ: CHRS) Right Now?
The 36-month beta value for CHRS is at 0.87. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CHRS is 105.41M, and currently, shorts hold a 30.30% of that float. The average trading volume for CHRS on June 27, 2025 was 1.57M shares.
CHRS) stock’s latest price update
The stock price of Coherus Oncology Inc (NASDAQ: CHRS) has surged by 1.34 when compared to previous closing price of 0.73, but the company has seen a -0.64% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-12 that Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers – Head, Investor Relations Denny Lanfear – Chief Executive Officer Theresa LaVallee – Chief Scientific & Development Officer Rosh Dias – Chief Medical Officer Sameer Goregaoker – Executive Vice President, Commercial Bryan McMichael – Chief Financial Officer Conference Call Participants Kripa Devarakonda – Truist Securities Brian Cheng – JPMorgan Mike Nedelcovych – TD Cowen Colleen Kusy – Baird Douglas Tsao – H.C. Wainwright Operator Good day and thank you for standing by.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -14.64% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.45% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRS starting from Wahlstrom Mats, who sale 99,988 shares at the price of $0.74 back on May 23 ’25. After this action, Wahlstrom Mats now owns 0 shares of Coherus Oncology Inc, valued at $73,881 using the latest closing price.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.58 for the present operating margin
- 0.56 for the gross margin
The net margin for Coherus Oncology Inc stands at -0.66. The total capital return value is set at -0.99.
Based on Coherus Oncology Inc (CHRS), the company’s capital structure generated 4.83 points at debt to capital in total, while cash flow to debt ratio is standing at 0.0. The debt to equity ratio resting at -1.26. The interest coverage ratio of the stock is -6.3.
Currently, EBITDA for the company is 60.94 million with net debt to EBITDA at -1.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.19. The receivables turnover for the company is 3.27for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.22.
Conclusion
In conclusion, Coherus Oncology Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
